VOYAGER: Avapritinib vs. regorafenib in unresectable or metastatic GIST

 

Trial name: Voyager
Agents: Avapritinib (formerly BLU-285) vs. regorafenib
Phase III
Status  Open, recruiting
Sponsor Blueprint Medicines Corporation

 

A Phase 3 study in patients with locally advanced unresectable or metastatic GIST (advanced GIST) of avapritinib versus regorafenib in patients previously treated with imatinib and 1 or 2 other tyrosine kinase inhibitors (TKIs).

Further information: https://www.clinicaltrials.gov/ct2/show/NCT03465722?term=avapritinib&recrs=ab&cond=GIST&rank=1

 

WHO is the trial for?

  • Adult patients with confirmed diagnosis of unresectable or metastatic GIST
  • Patients with a GIST tumour that has progressed or responded inadequately, or who experienced intolerance to previous therapy. Patients should have received imatinib and 1 or 2 other tyrosine kinase inhibitors (TKIs, including adjuvant therapy) before entering this study, but no more than 3 therapies.
  • Overall health status of the patient has to be good (ECOG performance status 0-2)

WHAT is the key question that this trial is attempting to answer?

This study assesses the efficacy of avapritinib compared to regorafenib in patients with advanced or metastatic GIST. It also evaluates the quality of life of patients in both therapy groups.

WHY patients might want to participate?

This clinical trial offers patients an opportunity to access a new therapy strategy. This trial will further support the research in GIST and potentially help other patients with this disease. Patients who may progress on regorafenib can cross-over to the avapritinib arm and patients who might progress on avapritinib, but still benefit from it, may continue on avapritinib.

The trial might or might not have benefit in your individual case.

More about the importance and benefits of joining clinical trials: Please click here.

WHEN will the trial be open?

 The study is open (recruiting).

WHERE is the trial available?

The trial is currently active for recruitment in the US, France, the UK, Australia, Sweden and the Republic of Korea. Further sites will open during 2018 - more than 80 study sites are planned to open globally. Please check for current information here or contact Blueprint Medicines below:

Study contact:

  • Blueprint Medicines
    Phone: +1-617-714-6707
    E-Mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

STUDY DESIGN: What does the study look like?

There are 2 study arms (groups): all participating patients will be randomly divided (by a computer) in two groups. One group will be assigned to avapritinib, the other group will receive regorafenib.

Patients on regorafenib whose disease is progressing (confirmed by central laboratory) may crossover to avapritinib.

 

 SPAEN Study Registry AvapritinibBLU Voyager

 

HOW do I get more information?

Patient organisations supporting GIST and/or sarcoma patients in your country may offer additional information about the trial, current recruitment status, and key contacts. Click here for a list of patient organisations serving GIST and/or sarcoma patients. If there are no such organisation in your country, please email us for more information: This email address is being protected from spambots. You need JavaScript enabled to view it.

SHARE your experience

You want to share your experience on this trial?
Send us an e-mail to: This email address is being protected from spambots. You need JavaScript enabled to view it.
Note that your experience would be helpful for other patients and patient organisations.

RESULTS of the study

No results are available at this time. Future results will be linked here.

 

Disclaimer: This is a patient-friendly summary of the clinical trial which has been provided for informational purposes only. Patients should consult their physician about any clinical trial opportunity.

Merken